Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mochida Pharmaceutical Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Mochida Pharmaceutical Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mochida Pharmaceutical Co (TSE:4534) has a Buyback Yield % of 0.00 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mochida Pharmaceutical Co and its competitors. Over the past decade, Mochida Pharmaceutical Co's Buyback Yield % has ranged from 0.01 to 3.07. According to the industry distribution chart, Mochida Pharmaceutical Co ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Mochida Pharmaceutical Co's Buyback Yield % too high?
Mochida Pharmaceutical Co's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 3.07. Based on the distribution chart, Mochida Pharmaceutical Co ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mochida Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mochida Pharmaceutical Co ranks #999999 out of 291 companies for Buyback Yield %. This places Mochida Pharmaceutical Co in the lower half of its industry. Historically, Mochida Pharmaceutical Co's own Buyback Yield % has ranged from 0.01 to 3.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mochida Pharmaceutical Co and its competitors. Mochida Pharmaceutical Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Mochida Pharmaceutical Co (TSE:4534) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,681.84, compared to a current price of 円3,115.00 — trading 15.4% below its estimated fair value. The current Buyback Yield % is 0.00. Mochida Pharmaceutical Co's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mochida Pharmaceutical Co (TSE:4534), the current Buyback Yield % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mochida Pharmaceutical Co (TSE:4534) Overvalued in 2026?
Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円3,115.00 is trading 15.4% below its estimated GF Value™ of 円3,681.84.
GuruFocus considers Mochida Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4534:
Buyback Yield %: 0.00
GF Value™: 円3,681.84 vs. price of 円3,115.00 (15.4% below fair value)
No single metric tells the full story. See the TSE:4534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
63GF Score
Get the complete analysis for TSE:4534
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4534 has been successfully added to your 
